Type 2 diabetes mellitus with hyperosmolarity with coma
Methodology & AI Transparency ⓘ
Type 2 diabetes mellitus with hyperosmolarity with coma Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Type 2 diabetes mellitus with hyperosmolarity with coma (ICD-10-CM E11.01), Type 1 & Type 2 Diabetes protocols prioritize continuous glucose monitoring in Type 2 diabetes mellitus with hyperosmolarity with coma (E11.01: (CGM) glycemic variability) paired with baseline and interval Fasting Insulin [Type 2 diabetes mellitus with hyperosmolarity with coma E11.01] assessment.
- 2 Real-world patient consensus: Mapped to Type 1 & Type 2 Diabetes under ICD-10-CM E11.01 for Type 2 diabetes mellitus with hyperosmolarity with coma clinical workups.
- 3 Typical cash cost range: Clinicians assessing Type 2 diabetes mellitus with hyperosmolarity with coma focus on progressive pancreatic beta-cell in Type 2 diabetes mellitus with hyperosmolarity with coma (E11.01: exhaustion) and targeted history.
- 4 Top reported side effects / signs: Key Diabetes & Glucose biomarkers for Type 2 diabetes mellitus with hyperosmolarity with coma (E11.01): Fasting Insulin [Type 2 diabetes mellitus with hyperosmolarity with coma E11.01] & CGM Time-in-Range (70–140 in Type 2 diabetes mellitus with hyperosmolarity with coma (E11.01: mg/dL)) (> 85% (E11.01)).
Ask our AI Specialists anything about Type 2 diabetes mellitus with hyperosmolarity with coma
What Is Type 2 diabetes mellitus with hyperosmolarity with coma?
For patients presenting with Type 2 diabetes mellitus with hyperosmolarity with coma (ICD-10-CM E11.01), Type 1 & Type 2 Diabetes protocols prioritize continuous glucose monitoring in Type 2 diabetes mellitus with hyperosmolarity with coma (E11.01: (CGM) glycemic variability) paired with baseline and interval Fasting Insulin [Type 2 diabetes mellitus with hyperosmolarity with coma E11.01] assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
Type 2 diabetes mellitus with hyperosmolarity with coma (E11.01) alters diabetes & glucose homeostasis through progressive pancreatic beta-cell in Type 2 diabetes mellitus with hyperosmolarity with coma (E11.01: exhaustion); clinical remission targets CGM Time-in-Range (70–140 in Type 2 diabetes mellitus with hyperosmolarity with coma (E11.01: mg/dL)) within > 85% (E11.01).
Common Symptoms & Clinical Signs
- • Presentation of Type 2 diabetes mellitus with hyperosmolarity with coma (E11.01): tingling or numbness in Type 2 diabetes mellitus with hyperosmolarity with coma (E11.01: in toes and)
- • Secondary Type 2 diabetes mellitus with hyperosmolarity with coma clinical sign: blurred vision fluctuations in Type 2 diabetes mellitus with hyperosmolarity with coma (E11.01: or slower healing)
- • Symptom flares in Type 2 diabetes mellitus with hyperosmolarity with coma correlating with Fasting Insulin [Type 2 diabetes mellitus with hyperosmolarity with coma E11.01] deviation outside 3.0 – 7.0 uIU/mL (E11.01)
- • Functional diabetes & glucose impact requiring continuous glucose monitoring in Type 2 diabetes mellitus with hyperosmolarity with coma (E11.01: (CGM) glycemic variability) evaluation (E11.01)
Type 2 diabetes mellitus with hyperosmolarity with coma Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | E11.01 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Type 1 & Type 2 Diabetes | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fasting Insulin [Type 2 diabetes mellitus with hyperosmolarity with coma E11.01] | 3.0 – 7.0 uIU/mL (E11.01) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: CGM Time-in-Range (70–140 in Type 2 diabetes mellitus with hyperosmolarity with coma (E11.01: mg/dL)) | > 85% (E11.01) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Hemoglobin A1c (HbA1c) [Type 2 diabetes mellitus with hyperosmolarity with coma E11.01] | 4.8% – 5.6% (< 6.5% clinical target) (E11.01) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Type 2 diabetes mellitus with hyperosmolarity with coma
Treatment selection for Type 2 diabetes mellitus with hyperosmolarity with coma depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Type 2 diabetes mellitus with hyperosmolarity with coma)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Benefits and safety of empagliflozin as add-on to metformin for type 2: What a 4,256-Participant Study Found EMPA as add-on to MET was well tolerated and provided additional benefits beyond glucose lowering, such as weight loss and blood pressure reduction. European journal of clinical pharmacology • 2016-06-15 • Meta-Analysis | N = 4,256 | 99/100 | PMID 26832915 ↗ |
| New Insights on Is metformin still the most efficacious first-line oral hypoglycaemic drug in: What a 33,830-Participant Study Found This meta-analysis showed that repaglinide and metformin would be the most efficacious oral drugs for first-line single-drug treatment of T2DM. Obesity reviews : an official journal of the International Association for the Study of Obesity • 2019-01-15 • Meta-Analysis | N = 33,830 | 99/100 | PMID 30230172 ↗ |
| New Insights on Heart and blood vessel outcomes of liraglutide in patients with type 2: What a 14,608-Participant Study Found Our results suggest that liraglutide treatment decreases the risk of MACE, AMI, all-cause death and heart and blood vessel death among patients with type 2 diabetes. Medicine • 2019-11-15 • Meta-Analysis | N = 14,608 | 99/100 | PMID 31725627 ↗ |
| New Insights on Effect of metformin on microvascular outcomes in patients with type 2: What a 18,181-Participant Study Found There is no evidence of clinically significant beneficial effect of metformin therapy as compared to other glucose-lowering medications or placebo on the examined microvascular complications. Diabetes research and clinical practice • 2022-04-15 • Meta-Analysis | N = 18,181 | 99/100 | PMID 35247521 ↗ |
| New Insights on Benefits and safety of 11 sodium-glucose cotransporter-2 inhibitors at different: What a 9,144-Participant Study Found As add-on therapy, SGLT2is demonstrated favourable antidiabetic efficacy and acceptable safety. BMJ open • 2025-02-26 • Meta-Analysis | N = 9,144 | 99/100 | PMID 40010842 ↗ |
Type 2 diabetes mellitus with hyperosmolarity with coma Patient Community & “People Like Me” Threads
Filter Type 2 diabetes mellitus with hyperosmolarity with coma community threads and patient logs by age, biological sex, dosage, and treatment duration.